02 October 2008
Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience
M. Fared K. SuriADEF, Haitham M. HusseinBCE, Mohamed M. AbdelmoulaBC, Afshin A. DivaniEG, Adnan I QureshiADEFMed Sci Monit 2008; 14(10): PI39-44 :: ID: 869394
Abstract
Background
There is a high risk of recurrence within the first 72 hours of ischemic stroke. Without bolus, the peak effect of clopidogrel may be delayed for 72 hours. A bolus may shorten this time but its safety in acute ischemic stroke is unknown.
Material and Method
All patients with acute ischemic stroke or transient ischemic attack within a 10 month period were administered 600 mg clopidogrel bolus if they were already taking aspirin regularly, or had aspirin allergy or intolerance. Demographic data, duration to initiation of therapy, National Institute of Health Stroke Scale score (NIHSSS) at baseline and at 24 hours were collected. Brain imaging studies were reviewed for hemorrhagic transformation. Wilcoxin rank sum test was used for comparison of NIHSSS over time.
Results
A total of 20 patients (mean age 66+/-14, men n=8) were loaded with clopidogrel because of aspirin failure (n=16), aspirin allergy (n=1), aspirin intolerance secondary to gastritis (n=2) or stent placement in the setting of acute stroke (n=1). Median time interval between clopidogrel bolus and symptom onset was 25 hours. The median NIHSSS at 24 hours (1, range 0-15) was significantly (p<0.01) lower than the NIHSSS at baseline (3, range 0-24). Neurological deterioration (NIHSSS increase > or =4 points) or hemorrhagic transformation was not seen in any patient.
Conclusions
A 600 mg clopidogrel bolus prior to initiating regular dose clopidogrel in the setting of acute ischemic stroke was safe. The potential for risk reduction in early recurrent stroke needs to be studied in future studies.
Keywords: Stroke - prevention & control, Recurrence, Prospective Studies, Platelet Aggregation Inhibitors - therapeutic use, Brain Ischemia - prevention & control, Aspirin - therapeutic use, Ticlopidine - therapeutic use, Aged, 80 and over
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952